2611005572
  • Open Access
  • Review

Application of Molecular Dynamics Simulations in Vaccine Design for Arboviruses

  • Day-Yu Chao 1,2,3

Received: 26 August 2026 | Revised: 02 November 2026 | Accepted: 04 November 2026 | Published: 12 November 2026

Abstract

Arboviruses, which comprise three virus families, are a diverse group of viruses transmitted by insects. While most arboviral diseases remain zoonotic and persist in a sylvatic cycle, some viruses, such as dengue (DENV) and chikungunya (CHIKV), have adapted to an urban cycle, with humans as the primary amplification host, causing significant medical consequences. While the live-attenuated (LA) vaccine against yellow fever virus has proven successful in providing protective immunity, safety concerns about other LA vaccines against DENV and CHIKV remain. Enveloped virus-like particles (eVLPs) have emerged as a leading vaccine platform for arboviruses, including dengue, Zika, and chikungunya, because they recapitulate the antigenic surface of authentic virions without infectious risk. Yet most eVLPs lack solved structures, and the interaction between the envelope protein and the lipid bilayers remains unknown, leaving key questions about assembly, stability, and immunogenicity unresolved. This review examines how molecular dynamics (MD) simulations, spanning all-atom and coarse-grained resolutions and increasingly deployed in multiscale workflows, are being integrated with cryo-electron microscopy to address these gaps. Structural comparisons show that flavivirus eVLPs typically adopt T = 1 icosahedral symmetry built from the same asymmetric prM-E trimer that organizes T = 3 virions. MD studies of dengue eVLPs reveal how E-M protein clusters act as membrane-bending units, and how in silico mutagenesis of lipid-facing residues can be translated into experimentally validated, secretion-enhancing eVLP variants. MD simulation has matured from a descriptive tool into an active driver of rational eVLP engineering, and its continued integration with cryo-EM, AI-accelerated force fields, and enhanced sampling methods will be essential for next-generation arbovirus vaccine design.

Graphical Abstract

References 

  • 1.

    Young, P.R. Arboviruses: A Family on the Move. Adv. Exp. Med. Biol. 2018, 1062, 1–10. https://doi.org/10.1007/978-981-10-8727-1_1.

  • 2.

    Weaver, S.C.; Reisen, W.K. Present and future arboviral threats. Antivir. Res. 2010, 85, 328–345. https://doi.org/10.1016/j.antiviral.2009.10.008.

  • 3.

    Bhatt, S.; Gething, P.W.; Brady, O.J.; et al. The global distribution and burden of dengue. Nature 2013, 496, 504–507. https://doi.org/10.1038/nature12060.

  • 4.

    Quan, N.K.; Taylor-Robinson, A.W. The Second Silent Pandemic: Why Arboviruses Demand an Orchestrated Global Health Response. Pathogens 2026, 15, 398. https://doi.org/10.3390/pathogens15040398.

  • 5.

    Gupta, H.; Barde, P.V.; Singh, M.P.; et al. A comprehensive overview of the burden, prevention, and therapeutic aspects of arboviral diseases in India. Commun. Med. 2025, 5, 254. https://doi.org/10.1038/s43856-025-00968-7.

  • 6.

    Lim, A.; Shearer, F.M.; Sewalk, K.; et al. The overlapping global distribution of dengue, chikungunya, Zika and yellow fever. Nat. Commun. 2025, 16, 3418. https://doi.org/10.1038/s41467-025-58609-5.

  • 7.

    Zhang, Y.; Liu, X.; Wu, Z.; et al. Oropouche virus: A neglected global arboviral threat. Virus Res. 2024, 341, 199318. https://doi.org/10.1016/j.virusres.2024.199318.

  • 8.

    Gould, E.A.; Higgs, S.; Buckley, A.; et al. Potential Arbovirus Emergence and Implications for the United Kingdom. Emerg. Infect. Dis. 2006, 12, 549–555. https://doi.org/10.3201/eid1204.051010.

  • 9.

    Siew, Z.Y.; Seow, I.; Lim, X.R.; et al. Arboviruses: The hidden danger of the tropics. Arch. Virol. 2025, 170, 140. https://doi.org/10.1007/s00705-025-06314-5.

  • 10.

    Mukhopadhyay, S.; Kuhn, R.J.; Rossmann, M.G. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 2005, 3, 13–22. https://doi.org/10.1038/nrmicro1067.

  • 11.

    Ivanova, P.T.; Myers, D.S.; Milne, S.B.; et al. Lipid composition of viral envelope of three strains of influenza virus—Not all viruses are created equal. ACS Infect. Dis. 2015, 1, 399–452. https://doi.org/10.1021/acsinfecdis.5b00040.

  • 12.

    Barrows, N.J.; Campos, R.K.; Liao, K.C.; et al. Biochemistry and Molecular Biology of Flaviviruses. Chem. Rev. 2018, 118, 4448–4482. https://doi.org/10.1021/acs.chemrev.7b00719.

  • 13.

    Mohsen, M.O.; Bachmann, M.F. Virus-like particle vaccinology, from bench to bedside. Cell. Mol. Immunol. 2022, 19, 993–1011. https://doi.org/10.1038/s41423-022-00897-8.

  • 14.

    Pijlman, G.P. Enveloped virus-like particles as vaccines against pathogenic arboviruses. Biotechnol. J. 2015, 10, 659–670. https://doi.org/10.1002/biot.201400427.

  • 15.

    Pitoiset, F.; Vazquez, T.; Bellier, B. Enveloped virus-like particle platforms: Vaccines of the future? Expert Rev. Vaccines 2015, 14, 913–915. https://doi.org/10.1586/14760584.2015.1046440.

  • 16.

    Pereira Cabral, B.; da Graça Derengowski Fonseca, M.; Mota, F.B. Long term prevention and vector control of arboviral diseases: What does the future hold? Int. J. Infect. Dis. 2019, 89, 169–174. https://doi.org/10.1016/j.ijid.2019.10.002.

  • 17.

    Rey, F.A.; Stiasny, K.; Heinz, F.X. Flavivirus structural heterogeneity: Implications for cell entry. Curr. Opin. Virol. 2017, 24, 132–139. https://doi.org/10.1016/j.coviro.2017.06.009.

  • 18.

    Palur, V.R.; Chen, G.W.; Chao, D.Y.; et al. Multiscale Simulations and Cryo-Electron Microscopy Reveal the Transition Pathway of Dengue Virus-like Particle Nanoassembly. ACS Nano 2026, 20, 6845–6863. https://doi.org/10.1021/acsnano.5c17047.

  • 19.

    Shen, W.F.; Galula, J.U.; Liu, J.H.; et al. Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody. eLife 2018, 7, e38970. https://doi.org/10.7554/elife.38970.

  • 20.

    Johnson, A.; Dodes Traian, M.; Walsh, R.M.; et al. Octahedral small virus-like particles of dengue virus type 2. J. Virol. 2025, 99, e0180924. https://doi.org/10.1128/jvi.01809-24.

  • 21.

    Urakami, A.; Sakurai, A.; Ishikawa, M.; et al. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus. Clin. Vaccine Immunol. 2017, 24, e00090-17. https://doi.org/10.1128/cvi.00090-17.

  • 22.

    Raju, S.; Adams, L.J.; Earnest, J.T.; et al. A chikungunya virus–like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Sci. Transl. Med. 2023, 15, eade8273. https://doi.org/10.1126/scitranslmed.ade8273.

  • 23.

    Johnson, J.E.; Chiu, W. Structures of virus and virus-like particles. Curr. Opin. Struct. Biol. 2000, 10, 229–235. https://doi.org/10.1016/s0959-440x(00)00073-7.

  • 24.

    Lynch, D.L.; Pavlova, A.; Fan, Z.; et al. Understanding Virus Structure and Dynamics through Molecular Simulations. J. Chem. Theory Comput. 2023, 19, 3025–3036. https://doi.org/10.1021/acs.jctc.3c00116.

  • 25.

    Reddy, T.; Sansom, M.S.P. Computational virology: From the inside out. Biochim. et Biophys. Acta BBA-Biomembr. 2016, 1858, 1610–1618. https://doi.org/10.1016/j.bbamem.2016.02.007.

  • 26.

    Cioffi, M.D. Role of lipid composition on human plasma membrane interactions with the Ebola virus matrix protein VP40. Biophys. J. 2023, 122, 506a–507a. https://doi.org/10.1016/j.bpj.2022.11.2698.

  • 27.

    Wang, Z.; Qiu, M.; Ji, Y.; et al. Palmitoylation of SARS-CoV-2 Envelope protein is central to virus particle formation. J. Virol. 2024, 98, e01072-24. https://doi.org/10.1128/jvi.01072-24.

  • 28.

    Carravilla, P.; Darré, L.; Oar-Arteta, I.R.; et al. The Bilayer Collective Properties Govern the Interaction of an HIV-1 Antibody with the Viral Membrane. Biophys. J. 2020, 118, 44–56. https://doi.org/10.1016/j.bpj.2019.11.005.

  • 29.

    de Oliveira dos Santos Soares, R.; Bortot, L.O.; van der Spoel, D.; et al. Membrane vesiculation induced by proteins of the dengue virus envelope studied by molecular dynamics simulations. J. Phys. Condens. Matter 2017, 29, 504002. https://doi.org/10.1088/1361-648x/aa99c6.

  • 30.

    Palur, V.R.; Chen, F.C.; Wu, S.R.; et al. An integrative approach to rational engineering of dengue virus-like particles. Cell Rep. Phys. Sci. 2025, 6, 102814. https://doi.org/10.1016/j.xcrp.2025.102814.

  • 31.

    Johnson, K.A.; Budicini, M.R.; Bhattarai, N.; et al. PI(4,5)P2 binding sites in the Ebola virus matrix protein VP40 modulate assembly and budding. J. Lipid Res. 2024, 65, 100512. https://doi.org/10.1016/j.jlr.2024.100512.

  • 32.

    Marzinek, J.K.; Raghuvamsi Palur, V.; Salem, G.; et al. Uncovering the conformational dynamics of dengue virus and its virus-like particles as novel vaccine candidates. Biophys. J. 2023, 122, 508a–509a. https://doi.org/10.1016/j.bpj.2022.11.2709.

  • 33.

    Yang, R.; Wu, S.; Wang, S.; et al. Refinement of SARS-CoV-2 envelope protein structure in a native-like environment by molecular dynamics simulations. Front. Mol. Biosci. 2022, 9, 1027223. https://doi.org/10.3389/fmolb.2022.1027223.

  • 34.

    Chlanda, P.; Mekhedov, E.; Waters, H.; et al. Palmitoylation Contributes to Membrane Curvature in Influenza A Virus Assembly and Hemagglutinin-Mediated Membrane Fusion. J. Virol. 2017, 91, e00947-17. https://doi.org/10.1128/jvi.00947-17.

  • 35.

    Cui, T.; Zhou, Y.; Wang, T. Recent advances in artificial intelligence–driven biomolecular dynamics simulations based on machine learning force fields. Curr. Opin. Struct. Biol. 2025, 95, 103191. https://doi.org/10.1016/j.sbi.2025.103191.

  • 36.

    Chu, X.; Wang, Y.; Tian, P.; et al. Editorial: Advanced Sampling and Modeling in Molecular Simulations for Slow and Large-Scale Biomolecular Dynamics. Front. Mol. Biosci. 2021, 8, 795991. https://doi.org/10.3389/fmolb.2021.795991.

  • 37.

    Hanson, G.; Adams, J.; Kepgang, D.I.B.; et al. Machine learning and molecular docking prediction of potential inhibitors against dengue virus. Front. Chem 2024, 12, 1510029.

  • 38.

    Dey, D.; Borkotoky, S.; Banerjee, M. In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor. Comput. Biol. Med. 2020, 127, 104063. https://doi.org/10.1016/j.compbiomed.2020.104063.

  • 39.

    Durham, N.D.; Jain, A.; Howard, A.; et al. Molecular basis for the increased fusion activity of the Ebola virus glycoprotein epidemic variant A82V: Insights from simulations and experiments. Cell Rep. 2025, 44, 115521. https://doi.org/10.1016/j.celrep.2025.115521.

Share this article:
How to Cite
Chao, D.-Y. Application of Molecular Dynamics Simulations in Vaccine Design for Arboviruses. eMicrobe 2026, 2 (4), 19. https://doi.org/10.53941/emicrobe.2026.100019.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.
Article Metrics
36
Article Views
0
Citations